Evidence map›Paper›PMID 40097686›Full record

ArticleAnalytical and bioanalytical chemistry2025

Comparative analysis of glycoproteomic software using a tailored glycan database.

Reuben A Hogan, Lauren E Pepi, Nicholas M Riley, Robert J Chalkley

Abstract readComparative Study
In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. UnderstandingJournal of the American Society for Mass Spectrometry · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Reuben A HoganUniversity of California, San Francisco, San Francisco, CA, USA. reuben.hogan@ucsf.edu.ORCID http://orcid.org/0000-0001-6375-2494
Lauren E PepiBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Nicholas M RileyUniversity of Washington, Seattle, WA, USA.
Robert J ChalkleyUniversity of California, San Francisco, San Francisco, CA, USA.

Funding

Proteomic and Genetic Approaches Defining Apolipoprotein E4 Neuropathologic MechanismsRF1AG059751 · NIA · J. DAVID GLADSTONE INSTITUTES · PI KROGAN, NEVAN J, MAHLEY, ROBERT W. · 2019 to 2019
$4.7M
Capturing the Holistic Glycocode through Systems GlycobiologyR00GM147304 · NIGMS · UNIVERSITY OF WASHINGTON · PI Nicholas M Riley · 2024 to 2026
$747k
NIA NIH HHS R01AG059751NIA NIH HHS RF1 AG059751NIGMS NIH HHS R00 GM147304NIGMS NIH HHS R00GM147304
6 · The paper itself

Abstract

Glycoproteomics is a rapidly developing field, and data analysis has been stimulated by several technological innovations. As a result, there are many software tools from which to choose; and each comes with unique features that can be difficult to compare. This work presents a head-to-head comparison of five modern analytical software: Byonic, Protein Prospector, MSFraggerGlyco, pGlyco3, and GlycoDecipher. To enable a meaningful comparison, parameter variables were minimized. One potential confounding variable is the glycan database that informs glycoproteomic searches. We performed glycomic profiling of the samples and used the output to construct matched glycan databases for each software. Up to 17,000 glycopeptide spectra were identified across three replicates of wild-type SH-SY5Y cells. There was overlap among all software for glycoproteins identified, locations of glycosites, and glycans; but there was no clear winner. Incorporation of several comparative criteria was critically important for learning the most information in this study and should be used more broadly when assessing software. A single criterion, such as number of glycopeptide spectra found, is not sufficient. We present evidence that suggests Byonic reports many spurious results at the glycoprotein and glycosite level. Overall, our results indicate that glycoproteomic searches should involve more than one software, excluding the current version of Byonic, to generate confidence by consensus. It may be useful to consider software with peptide-first approaches and with glycan-first approaches.

Indexed as

GlycoproteinsPolysaccharidesProteomicsSoftwareDatabases, FactualGlycopeptidesHumansGlycopeptidesGlycoproteinsPolysaccharidesComparisonGlycoproteomicsGlycoproteomic software

Identifiers

PMID40097686
PMCPMC12060194

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.